Our business model is based on license in/out and M&A. We make our assets both through in-house discovery and open collaboration with external organization. After the Therasid Bioscience’s R&D processes for each stage of assets, license-out or M&A activities will be initiated to global mid size pharma/biotech or local big-pharma in Korea.
There are four possible exit ways for investment, for example, in Korean market situation.
For sustainable company in Korean stock market after IPO, we are preparing cash-flow business by the diversification of business for creating annual sales.